Loading
OTS-P22 is an experimental peptide drug conjugate from Oncotherapy Solutions, being prepared for triple-negative breast cancer and other solid tumours. It has not yet been tested in people.
OTS-P22 is Oncotherapy Solutions' most advanced preclinical peptide drug conjugate. The company reports high stability in human plasma in vitro and complete tumour growth inhibition in an HCC1806 triple-negative breast cancer model in mice after one intravenous dose of 1.4 mg/kg, and plans IND-enabling studies for triple-negative breast, metastatic ovarian and endometrial cancers. No registered trial was found.
A peptide drug conjugate that, according to Oncotherapy Solutions, targets a receptor highly expressed in many solid tumours and carries a cytotoxic payload into the cell.
1.OTS-P22's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OTS-P22" OR ABSTRACT:"OTS-P22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OTS-P22, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/